Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia

计划入组 73 人 · 首次发布于 2026 年 1 月 15 日

A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors

计划入组 130 人 · 首次发布于 2026 年 9 月 8 日

NTX-301 in MDS/AML

计划入组 22 人 · 首次发布于 2019 年 11 月 19 日

AMT-253

NTX-0250

NTX-470

NTX Catalyst Health Network, Inc.

United States

Innovation Pharmaceuticals, Inc.

United States

COCHIN HOSPITAL

India

Neurosterix Initiates Phase 1 Trial of NTX-253, Novel M4 Receptor Modulator for Schizophrenia Treatment

Neuraptive's NTX-001 Receives FDA Breakthrough Therapy Designation for Peripheral Nerve Injury

Epigenetic Therapy NTX-301 Activates Hippo Pathway to Overcome Treatment-Resistant AML